logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Caocao Mobility (02643.HK) repurchased 39,300 shares on October 28 for approximately HK$390,400.

date
28/10/2026
Zhitong Finance APP News, Cao Cao Mobility (02643.HK) announced that on October 28, 2026, it spent approximately HK$390,400 to repurchase 39,300 shares.
Latest
2 m ago
Weihua New Materials (603310.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 37.06 million yuan, a year-on-year decrease of 65.86%.
4 m ago
Xinxiang Chemical Fiber (000949.SZ) released its first three quarters results, with net profit attributable to shareholders of RMB 547 million, up 310.86% year on year.
5 m ago
Tahe Intelligent (603656.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 30.6 million yuan, a year-on-year increase of 6.33%.
6 m ago
Yuanxin Industry (301053.SZ) released its first three quarters performance, with net profit attributable to the parent company of 31.0032 million yuan, a year-on-year increase of 110.73%.
8 m ago
Junshi Biosciences (01877.HK): The marketing application for a new indication of toripalimab injection (subcutaneous injection) for first-line treatment of HER2-expressing urothelial carcinoma has been accepted.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.